<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab13">
 <label>Table 28.13</label>
 <caption>
  <p>Antiretroviral agents used in the treatment of HIV infection</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Drugs</th>
    <th>Mechanisms of action</th>
    <th>Mechanisms of resistance</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Nucleoside analogues</td>
    <td>Analogues of normal nucleosides</td>
    <td rowspan="7">Thymidine analogue mutations promote ATP-mediated and pyrophosphate-mediated excision of the incorporated terminator M184V or Q151M complex mutations and impair incorporation of nucleoside analogues</td>
   </tr>
   <tr>
    <td>Zidovudine</td>
    <td>Active as triphosphate derivatives</td>
   </tr>
   <tr>
    <td>Stavudine</td>
    <td>Incorporated into nascent viral DNA</td>
   </tr>
   <tr>
    <td>Lamivudine</td>
    <td rowspan="4">Prematurely terminate HIV DNA synthesis</td>
   </tr>
   <tr>
    <td>Didanosine</td>
   </tr>
   <tr>
    <td>Zalcitabine</td>
   </tr>
   <tr>
    <td>Abacavir</td>
   </tr>
   <tr>
    <td>Nucleotide analogues</td>
    <td rowspan="2">Same as nucleoside analogues</td>
    <td rowspan="2">K65 R impairs incorporation of tenofovir into DNA thymidine analogue mutations often associated with cross-resistance to tenofovir</td>
   </tr>
   <tr>
    <td>Tenofovir</td>
   </tr>
   <tr>
    <td>Nucleoside reverse transcriptase inhibitors</td>
    <td>Bind a hydrophobic pocket of HIV type 1 reverse transcriptase</td>
    <td>Mutations reduce affinity of the inhibitors for the enzyme</td>
   </tr>
   <tr>
    <td>Nevirapine</td>
    <td>Block polymerization of viral DNA</td>
    <td rowspan="3">Single mutations generally sufficient to induce high level of resistance</td>
   </tr>
   <tr>
    <td>Efavirenz</td>
    <td rowspan="2">Inactive against HIV type 2</td>
   </tr>
   <tr>
    <td>Delavirdine</td>
   </tr>
   <tr>
    <td>Protease inhibitors</td>
    <td rowspan="2">Structure derived from natural peptidic substrates of HIV type 1 protease</td>
    <td rowspan="2">Mutations reduce affinity of the inhibitors for the enzyme</td>
   </tr>
   <tr>
    <td>Saquinavir</td>
   </tr>
   <tr>
    <td>Ritonovir</td>
    <td>Bind the active site of the protease</td>
    <td>High-level resistance requires accumulation of mutations</td>
   </tr>
   <tr>
    <td>Indinavir</td>
    <td rowspan="4"/>
    <td rowspan="4"/>
   </tr>
   <tr>
    <td>Nelfinavir</td>
   </tr>
   <tr>
    <td>Amprenavir</td>
   </tr>
   <tr>
    <td>Lopinavir</td>
   </tr>
   <tr>
    <td>Fusion inhibitors</td>
    <td>Thirty-six amino acid peptide derived from the HR2 domain of glycoprotein 41</td>
    <td rowspan="2">Mutations affect HR1, a domain of glycoprotein 41 whose interaction with HR-2 promotes membrane fusion</td>
   </tr>
   <tr>
    <td>Enfuvirtide</td>
    <td>Interferes with glycoprotein 41-dependent membrane fusion</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
